BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31486418)

  • 1. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
    Niu L; Gao Z; Cui Y; Yang X; Li H
    Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
    Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
    Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
    Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
    J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
    Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
    Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
    Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
    Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.
    Di S; Li M; Ma Z; Guo K; Li X; Yan X
    Pathol Res Pract; 2019 Jun; 215(6):152415. PubMed ID: 31064720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
    Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
    Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
    Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U
    Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
    Zhou XY; Shu XM
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
    Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
    Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer.
    Li A; Zhu X; Wang C; Yang S; Qiao Y; Qiao R; Zhang J
    Sci Rep; 2019 Mar; 9(1):5166. PubMed ID: 30914736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
    Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
    Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.
    Li Z; Liu J; Chen T; Sun R; Liu Z; Qiu B; Xu Y; Zhang Z
    J Exp Clin Cancer Res; 2021 Mar; 40(1):86. PubMed ID: 33648560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer.
    Zhang X; Zhou J; Xue D; Li Z; Liu Y; Dong L
    Int J Biol Macromol; 2019 May; 129():227-232. PubMed ID: 30685303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
    Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
    Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer.
    Dong L; Li Y; Xue D; Liu Y
    IUBMB Life; 2018 Apr; 70(4):291-299. PubMed ID: 29517839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.